Royalty Pharma plc
RPRX · Nasdaq
- $58.61
- $33.95B
- Open
- —
- —
- $57.75 - $59.55
- $34.63 - $64.38
- —
- —
- 2.97M
About Royalty Pharma plc
Royalty Pharma is a biopharmaceutical royalty company that generates revenue from portfolio receipts tied to pharmaceutical and biotechnology products. The supplied evidence identifies portfolio receipts and total income and other revenues, but does not provide a segment breakdown, customer list, royalty-acquisition structure, or product-level contribution mix. The company reported $2.4 billion of revenue and $0.8 billion of net income in FY2025, compared with $2.3 billion and $0.9 billion in FY2024. Its Q2 2026 results included $674 million of total income and other revenues and $736 million of adjusted EBITDA, indicating substantial operating scale.
Notable Price Movement
- Aug 3-7$56.772.84%
Royalty Pharma fell $2.49, or 4.15%, from $59.97 to $57.48 over the period, extending losses through four consecutive closes before a modest rebound on August 4. The stock declined $0.79 on July 29, $0.16 on July 30, and $0.59 on July 31, then dropped another $1.26 on August 3 before recovering $0.31. Supplied evidence does not identify a broad-market catalyst or establish the exact timing of the company-specific news relative to trading. The later Q2 update was mixed: earnings and revenue beat estimates by 3.94% and 1.52%, adjusted EBITDA rose to $736 million from $633 million, and 2026 portfolio-receipts guidance increased, but net income fell to $18 million from $32 million.
